First Time Loading...

Monopar Therapeutics Inc
NASDAQ:MNPR

Watchlist Manager
Monopar Therapeutics Inc Logo
Monopar Therapeutics Inc
NASDAQ:MNPR
Watchlist
Price: 0.6275 USD -4.49% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

MNPR's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. [ Read More ]

The intrinsic value of one MNPR stock under the Base Case scenario is 0.4163 USD. Compared to the current market price of 0.6275 USD, Monopar Therapeutics Inc is Overvalued by 34%.

Key Points:
MNPR Intrinsic Value
Base Case
0.4163 USD
Overvaluation 34%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Monopar Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MNPR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Monopar Therapeutics Inc

Provide an overview of the primary business activities
of Monopar Therapeutics Inc.

What unique competitive advantages
does Monopar Therapeutics Inc hold over its rivals?

What risks and challenges
does Monopar Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Monopar Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Monopar Therapeutics Inc.

Provide P/S
for Monopar Therapeutics Inc.

Provide P/E
for Monopar Therapeutics Inc.

Provide P/OCF
for Monopar Therapeutics Inc.

Provide P/FCFE
for Monopar Therapeutics Inc.

Provide P/B
for Monopar Therapeutics Inc.

Provide EV/S
for Monopar Therapeutics Inc.

Provide EV/GP
for Monopar Therapeutics Inc.

Provide EV/EBITDA
for Monopar Therapeutics Inc.

Provide EV/EBIT
for Monopar Therapeutics Inc.

Provide EV/OCF
for Monopar Therapeutics Inc.

Provide EV/FCFF
for Monopar Therapeutics Inc.

Provide EV/IC
for Monopar Therapeutics Inc.

Show me price targets
for Monopar Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Monopar Therapeutics Inc?

How accurate were the past Revenue estimates
for Monopar Therapeutics Inc?

What are the Net Income projections
for Monopar Therapeutics Inc?

How accurate were the past Net Income estimates
for Monopar Therapeutics Inc?

What are the EPS projections
for Monopar Therapeutics Inc?

How accurate were the past EPS estimates
for Monopar Therapeutics Inc?

What are the EBIT projections
for Monopar Therapeutics Inc?

How accurate were the past EBIT estimates
for Monopar Therapeutics Inc?

Compare the revenue forecasts
for Monopar Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Monopar Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Monopar Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Monopar Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Monopar Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Monopar Therapeutics Inc with its peers.

Analyze the financial leverage
of Monopar Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Monopar Therapeutics Inc.

Provide ROE
for Monopar Therapeutics Inc.

Provide ROA
for Monopar Therapeutics Inc.

Provide ROIC
for Monopar Therapeutics Inc.

Provide ROCE
for Monopar Therapeutics Inc.

Provide Gross Margin
for Monopar Therapeutics Inc.

Provide Operating Margin
for Monopar Therapeutics Inc.

Provide Net Margin
for Monopar Therapeutics Inc.

Provide FCF Margin
for Monopar Therapeutics Inc.

Show all solvency ratios
for Monopar Therapeutics Inc.

Provide D/E Ratio
for Monopar Therapeutics Inc.

Provide D/A Ratio
for Monopar Therapeutics Inc.

Provide Interest Coverage Ratio
for Monopar Therapeutics Inc.

Provide Altman Z-Score Ratio
for Monopar Therapeutics Inc.

Provide Quick Ratio
for Monopar Therapeutics Inc.

Provide Current Ratio
for Monopar Therapeutics Inc.

Provide Cash Ratio
for Monopar Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Monopar Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Monopar Therapeutics Inc?

What is the current Free Cash Flow
of Monopar Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Monopar Therapeutics Inc.

Financials

Balance Sheet Decomposition
Monopar Therapeutics Inc

Current Assets 7.3m
Cash & Short-Term Investments 7.3m
Other Current Assets 66.4k
Non-Current Assets 12.7k
PP&E 12.7k
Current Liabilities 1.8m
Accounts Payable 1.7m
Accrued Liabilities 8.4k
Other Current Liabilities -10
Efficiency

Earnings Waterfall
Monopar Therapeutics Inc

Revenue
0 USD
Operating Expenses
-8.8m USD
Operating Income
-8.8m USD
Other Expenses
429k USD
Net Income
-8.4m USD

Free Cash Flow Analysis
Monopar Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

MNPR Profitability Score
Profitability Due Diligence

Monopar Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional ROIC
Negative Free Cash Flow
Negative Operating Income
43/100
Profitability
Score

Monopar Therapeutics Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

MNPR Solvency Score
Solvency Due Diligence

Monopar Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Monopar Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MNPR Price Targets Summary
Monopar Therapeutics Inc

Wall Street analysts forecast MNPR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MNPR is 2.04 USD with a low forecast of 2.02 USD and a high forecast of 2.1 USD.

Lowest
Price Target
2.02 USD
222% Upside
Average
Price Target
2.04 USD
225% Upside
Highest
Price Target
2.1 USD
235% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MNPR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MNPR Price
Monopar Therapeutics Inc

1M 1M
-15%
6M 6M
+46%
1Y 1Y
-45%
3Y 3Y
-90%
5Y 5Y
-98%
10Y 10Y
-98%
Annual Price Range
0.6275
52w Low
0.289
52w High
1.35
Price Metrics
Average Annual Return -44.08%
Standard Deviation of Annual Returns 14.23%
Max Drawdown -99%
Shares Statistics
Market Capitalization 11m USD
Shares Outstanding 17 454 900
Percentage of Shares Shorted 3.32%

MNPR Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Monopar Therapeutics Inc Logo
Monopar Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

11m USD

Dividend Yield

0%

Description

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.

Contact

ILLINOIS
Wilmette
1000 Skokie Blvd Ste 350
+18473880349.0
https://www.monopartx.com/

IPO

2019-12-19

Employees

9

Officers

Co-Founder, CEO, President & Director
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
CFO, Secretary, Treasurer & Director
Ms. Kim R. Tsuchimoto CPA
Chief Operating Officer
Mr. Andrew J. Cittadine M.B.A.
Acting Chief Medical Officer
Dr. Patrice P. Rioux M.D., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one MNPR stock?

The intrinsic value of one MNPR stock under the Base Case scenario is 0.4163 USD.

Is MNPR stock undervalued or overvalued?

Compared to the current market price of 0.6275 USD, Monopar Therapeutics Inc is Overvalued by 34%.